Topical delivery of mTOR inhibitor halts scarring.
Topical delivery of mTOR inhibitor halts scarring.
复制标题
局部施用 mTOR 抑制剂可以阻止疤痕形成。
DOI:
10.1016/j.jdermsci.2019.06.008
复制
发表时间:
2019
影响因子:
4.6
通讯作者:
Squarize,CristianeH
中科院分区:
文献类型:
--
作者:
Webber,LianaP;Yip,Brian;NascimentoFilho,CarlosHVdo;Park,HaB;Castilho,RogerioM;Squarize,CristianeH
Scar management is considered a major medical need affecting patients with large wounds, extensive burns, and enhanced genetic susceptibility for scar formation. Scarring impacts the human’s well-being interfering with aesthetics, skin functions, and physical restriction of the body movement [1]. Scarring is not limited to the integumentary system (eg, skin), it also affects multiple organs like the respiratory and digestive (eg, lungs and salivary glands) systems, among others. Moreover, surgical interventions can also lead to undesired scarring and fibrosis, especially in the skin [2]. The development of novel pharmacological strategies targeting fibrosis and scarring constitute an urgent need to improve the lives of affected individuals. The biology of the scar formation is unique as it develops later after wound closure and during tissue maturation phase. Such a long course of scar formation provides a unique window of opportunity for pharmacological intervention.Current therapies offer limited results and mainly rely on enhanced skin hydration, moderate relieve of tissue tension, and protection against ultraviolet (UV). Conventional treatment includes a plethora of surgical and non-surgical strategies as pressure therapy, silicone gel, dermabrasion, chemical peels, as well as corticosteroid injections, and even the use of radiation and chemotherapy (eg, 5-fluorouracil or bleomycin). Most of the overthe-counter formulations contain ingredients like onion extract and vitamins A and E; however, the literature lacks well-designed studies to test their efficacy [3].